Show simple item record

dc.contributor.authorDe Miguel Pérez, Diego
dc.contributor.authorSerrano Fernández, María José 
dc.date.accessioned2022-06-27T10:37:09Z
dc.date.available2022-06-27T10:37:09Z
dc.date.issued2022-06-02
dc.identifier.citationde Miguel-Perez, D... [et al.]. Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer. J Exp Clin Cancer Res 41, 186 (2022). [https://doi.org/10.1186/s13046-022-02379-1]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/75680
dc.description.abstractBackground: Immune-checkpoint inhibitors (ICIs) changed the therapeutic landscape of patients with lung cancer. However, only a subset of them derived clinical benefit and evidenced the need to identify reliable predictive biomarkers. Liquid biopsy is the non-invasive and repeatable analysis of biological material in body fluids and a promising tool for cancer biomarkers discovery. In particular, there is growing evidence that extracellular vesicles (EVs) play an important role in tumor progression and in tumor-immune interactions. Thus, we evaluated whether extracellular vesicle PD-L1 expression could be used as a biomarker for prediction of durable treatment response and survival in patients with non-small cell lung cancer (NSCLC) undergoing treatment with ICIs. Methods: Dynamic changes in EV PD-L1 were analyzed in plasma samples collected before and at 9 ± 1 weeks during treatment in a retrospective and a prospective independent cohorts of 33 and 39 patients, respectively. Results: As a result, an increase in EV PD-L1 was observed in non-responders in comparison to responders and was an independent biomarker for shorter progression-free survival and overall survival. To the contrary, tissue PD-L1 expression, the commonly used biomarker, was not predictive neither for durable response nor survival. Conclusion: These findings indicate that EV PD-L1 dynamics could be used to stratify patients with advanced NSCLC who would experience durable benefit from ICIs.es_ES
dc.description.sponsorshipCenter for Thoracic Oncology Icahn School of Medicine at Mount Sinaies_ES
dc.description.sponsorshipBorsa Dottorati FSE XXXII ciclo Unimees_ES
dc.description.sponsorshipUnited States Department of Health & Human Serviceses_ES
dc.description.sponsorshipNational Institutes of Health (NIH) - USAes_ES
dc.description.sponsorshipNIH National Cancer Institute (NCI) P30CA016672es_ES
dc.description.sponsorshipUniversity of Pittsburgh Hillman Cancer Centeres_ES
dc.description.sponsorshipHillman Cancer Center's NCI Cancer Center Support Grant (CCSG) P30CA047904es_ES
dc.description.sponsorshipA.S.S.O. (Associazione Siciliana Sostegno Oncologico) Onluses_ES
dc.description.sponsorshipNational Cancer Institute-Cancer Center Support Grant (CCSG) P30CA134274es_ES
dc.description.sponsorshipMerck & Companyes_ES
dc.language.isoenges_ES
dc.publisherBMCes_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectExtracellular vesicleses_ES
dc.subjectPD-L1es_ES
dc.subjectBiomarkerses_ES
dc.subjectImmunotherapy es_ES
dc.subjectNSCLCes_ES
dc.titleExtracellular vesicle PD‑L1 dynamics predict durable response to immune‑checkpoint inhibitors and survival in patients with non‑small cell lung canceres_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.1186/s13046-022-02379-1
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Atribución 3.0 España
Except where otherwise noted, this item's license is described as Atribución 3.0 España